Search
Do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy
go.drugbank.com/conditions/DBCOND0115055Drugs: AmikacinSynonyms: Do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapyLormetazepam
go.drugbank.com/drugs/DB13872ApprovedLormatazepam is an orally available benzodiazepine used in the UK for the treatment of short-term insomnia [L927]. … It is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations.
Synonyms: 7-Chloro-1,3-dihydro-5-(o-chlorophenyl)-3-hydroxy-1-methyl-2H-1,4-benzodiazepin-2-one, 7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-2H-1,4-benzodiazepin-2-oneCategories: Heterocyclic Compounds, 2-RingCancer for Which Taxanes Are a Suitable Treatment Option
go.drugbank.com/conditions/DBCOND0050538Drugs: CapecitabineSynonyms: Cancer for Which Taxanes Are a Suitable Treatment OptionA confirmed ≥4 point increase in AUA symptom score
go.drugbank.com/conditions/DBCOND0119559Drugs: FinasterideSynonyms: A confirmed ≥4 point increase in AUA symptom score, A confirmed ≥4 point increase in AUA symptom scoreBiotin
go.drugbank.com/drugs/DB00121ApprovedInvestigationalNutraceuticalA water-soluble, enzyme co-factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk.
Synonyms: 5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid, (3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-valeric acidMixtures: One A Day Tab, Extra Once A DayGonadorelin
go.drugbank.com/drugs/DB00644ApprovedInvestigationalVet approvedIt is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pituitary.
Products: LH-RH FERRING 0,1 MG/ML IV ENJEKSIYONLUK COZELTI ICEREN AMPUL, 1 ADETBosentan
go.drugbank.com/drugs/DB00559ApprovedInvestigationalBosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals.
Mixtures: OCUBRAX® SUSPENSION OFTALMICA, OCUBRAX® SUSPENSION OFTALMICACategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InducersDisease progression with a PD-1 blocking antibody-based regimen
go.drugbank.com/conditions/DBCOND0174298Drugs: Vusolimogene oderparepvecSynonyms: Disease progression with a PD-1 blocking antibody-based regimenConditions where a reduction of gastric acid secretion is required
go.drugbank.com/conditions/DBCOND0117234Drugs: PantoprazoleSynonyms: Conditions where a reduction of gastric acid secretion is requiredSpironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigationalSpironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. … [A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243]
Mixtures: Benzoyl Peroxide 5% / Clindamycin 1% / Niacinamide 2% / Spironolactone 2%, Dapsone 6% / Niacinamide 2% / Spironolactone 5%Categories: P-glycoprotein inducers, Cytochrome P-450 CYP2C8 Inhibitors